Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with .
Helsinn Healthcare S.A.January 12, 2021 GMT
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
January 12, 2021 03:30 ET | Source: Helsinn Healthcare S.A. Helsinn Healthcare S.A. Lugano/Pazzallo, SWITZERLAND
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
TAS0953/HM06 is an investigational oral treatment which inhibits several RET abnormalities identified as oncogenic driver alterations in NSCLC, papillary and medullary thyroid cancers, and several other tumor types. This innovative drug candidate
(1)
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Lugano, Switzerland, January 12, 2021 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
TAS0953/HM06 is an investigational oral treatment which inhibits several RET abnormalities identified as oncogenic driver alterations in NSCLC, papillary and medullary thyroid cancers, and several other tumor types. This innovative drug candidate offers several differentiating features as compared to other RET inhibitors.
Epidermal growth factor receptor (
EGFR) mutations are seen in approximately 10-20% of patients with non-small cell lung cancer (NSCLC), with a higher percentage observed among Asian patients. But considering that over 200,000 people a year are diagnosed with lung cancer, that seemingly small percentage represents a lot of patients, said Roy Herbst, MD, PhD, chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut.
Over the past 2 decades, tyrosine kinase inhibitors (TKIs) targeting
EGFR have emerged, beginning with the two first-generation EGFR-TKIs, gefitinib (Iressa) and erlotinib (Tarceva).
A series of trials evaluating first- and second-generation EGFR TKIs found that erlotinib, gefitinib, and afatinib (Gilotrif) were the best first-line treatment options for patients with advanced NSCLC with
Aurora Kinase C Market Investment Analysis | AbbVie Inc, Sanofi | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.